Alpha 2.0
Login Register
» Articles » PMID: 25398246

A Novel Approach for Establishing Cardiovascular Drug Efficacy

Overview
Journal Nat Rev Drug Discov
Specialty Pharmacology
Date 2014 Nov 16
PMID 25398246
Citations 8
Authors
Hiddo J Lambers Heerspink
Diederick E Grobbee
Dick de Zeeuw
Affiliations
Soon will be listed here.
Citing Articles

Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.

Muskiet M, Tonneijck L, Smits M, Kramer M, Ouwens D, Hartmann B Diabetes Obes Metab. 2021; 24(1):115-124.

PMID: 34580975 PMC: 9293357. DOI: 10.1111/dom.14557.

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe.

Koomen J, Stevens J, Monster-Simons M, Heerspink H, Mol P Front Pharmacol. 2021; 12:626766.

PMID: 33995023 PMC: 8113630. DOI: 10.3389/fphar.2021.626766.

Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.

Koomen J, Stevens J, Heerspink H Br J Clin Pharmacol. 2020; 86(11):2192-2203.

PMID: 32311110 PMC: 7576615. DOI: 10.1111/bcp.14318.

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy.

de Zeeuw D, Heerspink H Nephrol Dial Transplant. 2020; 35(Suppl 2):ii38-ii42.

PMID: 32162661 PMC: 7066539. DOI: 10.1093/ndt/gfaa013.

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Idzerda N, Stefansson B, Pena M, Sjostrom D, Wheeler D, Heerspink H Nephrol Dial Transplant. 2019; 35(9):1570-1576.

PMID: 31005993 PMC: 7473803. DOI: 10.1093/ndt/gfz064.